Strategic partnerships Ichor Medical Systems has a history of collaboration with major biotech players such as AstraZeneca and Immunomic Therapeutics, indicating strong potential for licensing, co-development, or research partnerships to advance TriGrid platform applications and expand clinical programs.

Platform monetization The TriGrid delivery system serves as an enabling platform for DNA drug and vaccine delivery across multiple indications, suggesting sales opportunities with biopharma and biotech companies pursuing DNA therapies, monoclonal antibodies, or rapid response vaccine programs.

Targeted indications Active or potential interest areas include cancer (glioblastoma), infectious diseases (HBV, HIV, Ebola), and biodefense; these niches present collaboration or contract development opportunities with sponsors seeking electroporation-based delivery solutions.

Early-stage leverage With a small team and a revenue range indicative of being in development or contract-based work, Ichor may benefit from services that scale with partnerships, such as joint development agreements, milestone-based licensing, or contract research for plasmid DNA constructs.

Global collaboration Past multi-continent engagement (AstraZeneca, FIT Biotech, Immunomic Therapeutics) signals openness to international co-development; sales efforts could target large pharma, biotech clusters, and CROs seeking electroporation-enabled delivery capabilities.